Condition: Prostate Cancer · Sponsor: The Greater Poland Cancer Centre
The aim of this prospective phase II study is to evaluate the toxicity of salvage partial (focal) prostate brachytherapy in patients after prior radiotherapy (standard teleradiotherapy with / without brachytherapy, hypofractionated, self-reactive HDR / LDR brachytherapy) with local recurrence on the part of the prostate gland.
This description comes directly from the study's public registry record.
Wojciech Burchardt, PhD, MD · +48505149659 · wojciech.burchardt@wco.pl
Ewa Tańska, PhD, MSc. · +618850767 · ewa.tanska@wco.pl
Always discuss trial participation with your own doctor first.
| Greater Poland Cancer Centre / Brachytherapy Department | Poznan, Greater Poland Voivodeship, Poland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05715502